✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

FLOW Trial Results

Released: Last reviewed:

FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years.

Clinical referencePubMed-linked
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

FLOW (NEJM 2024, PMID 38785189): 24% reduction in major kidney/CV events in T2D + CKD over median 3.4 years.

PubMed citations

Related clinical pages

Key facts, checked November 20, 2026

FLOW (NEJM 2024) randomized 3,533 adults with type 2 diabetes and chronic kidney disease to weekly semaglutide or placebo. After a median 3.4 years, when a prespecified interim analysis recommended stopping early, the risk of a primary kidney or cardiovascular event was 24% lower with semaglutide (331 versus 410 first events; hazard ratio 0.76). Death from cardiovascular causes was also lower (hazard ratio 0.71), and kidney function declined 1.16 mL/min/1.73 m² a year more slowly. The Ozempic injection label now includes this kidney indication. FLOW tested Ozempic, not compounded semaglutide.